

Paolo Denti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1194134/publications.pdf>

Version: 2024-02-01

189
papers

5,949
citations

109321

35
h-index

102487

66
g-index

203
all docs

203
docs citations

203
times ranked

5360
citing authors

#	ARTICLE	IF	CITATIONS
1	Leveraging physiologically based pharmacokinetic modeling to optimize dosing for lopinavir/ritonavir with rifampin in pediatric patients. <i>Pharmacotherapy</i> , 2023, 43, 638-649.	2.6	2
2	Abacavir pharmacokinetics in African children living with HIV: A pooled analysis describing the effects of age, malnutrition and common concomitant medications. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 403-415.	2.4	2
3	Conservative, surgical, and percutaneous treatment for mitral regurgitation shortly after acute myocardial infarction. <i>European Heart Journal</i> , 2022, 43, 641-650.	2.2	36
4	Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosis. <i>Pharmacogenetics and Genomics</i> , 2022, 32, 24-30.	1.5	3
5	Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic Study. <i>Clinical Infectious Diseases</i> , 2022, 75, 141-151.	5.8	16
6	Predicting Drug-Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling. <i>Clinical Pharmacokinetics</i> , 2022, 61, 375-386.	3.5	4
7	One dose does not fit all: revising the WHO paediatric dosing tool to include the non-linear effect of body size and maturation. <i>The Lancet Child and Adolescent Health</i> , 2022, 6, 9-10.	5.6	8
8	Concentration-response relationships of dolutegravir and efavirenz with weight change after starting antiretroviral therapy. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 883-893.	2.4	9
9	Linezolid toxicity in patients with drug-resistant tuberculosis: a prospective cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1146-1154.	3.0	15
10	Pharmacogenetics of Between-Individual Variability in Plasma Clearance of Bedaquiline and Clofazimine in South Africa. <i>Journal of Infectious Diseases</i> , 2022, 226, 147-156.	4.0	8
11	Transcatheter lithotripsy to facilitate post-dilatation of underexpanded aortic transcatheter heart valve. <i>European Heart Journal</i> , 2022, 43, 2081-2081.	2.2	1
12	Population pharmacokinetics of ethambutol in African children: a pooled analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1949-1959.	3.0	3
13	Population Pharmacokinetics of Antimalarial Naphthoquine in Combination with Artemisinin in Tanzanian Children and Adults: Dose Optimization. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, , e0169621.	3.2	0
14	Bedaquiline exposure in pregnancy and breastfeeding in women with rifampicin-resistant tuberculosis. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3548-3558.	2.4	8
15	Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, , e0226421.	3.2	0
16	Pharmacogenetics of Dolutegravir Plasma Exposure Among Southern Africans With Human Immunodeficiency Virus. <i>Journal of Infectious Diseases</i> , 2022, 226, 1616-1625.	4.0	3
17	Population Pharmacokinetic Model and Alternative Dosing Regimens for Dolutegravir Coadministered with Rifampicin. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, .	3.2	5
18	Pretomanid Pharmacokinetics in the Presence of Rifamycins: Interim Results from a Randomized Trial among Patients with Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	17

#	ARTICLE	IF	CITATIONS
19	Is the EuroSCORE II reliable in surgical mitral valve repair? A single-centre validation study. <i>European Journal of Cardio-thoracic Surgery</i> , 2021, 59, 863-868.	1.4	13
20	Constructing a representative in silico population for paediatric simulations: Application to HIV-positive African children. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2847-2854.	2.4	15
21	Pharmacokinetics and Drug-Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1034-1044.	4.7	20
22	Pharmacokinetic profile of amodiaquine and its active metabolite desethylamodiaquine in Ghanaian patients with uncomplicated falciparum malaria. <i>Malaria Journal</i> , 2021, 20, 18.	2.3	8
23	Dolutegravir pharmacokinetics during co-administration with either artemether/lumefantrine or artesunate/amodiaquine. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1269-1272.	3.0	3
24	Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB Drugs. <i>Clinical Pharmacokinetics</i> , 2021, 60, 685-710.	3.5	39
25	Long-term results of tricuspid annuloplasty with 3-dimensional-shaped rings: effective and durable!. <i>European Journal of Cardio-thoracic Surgery</i> , 2021, 60, 115-121.	1.4	4
26	Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis. <i>International Journal of Infectious Diseases</i> , 2021, 105, 688-694.	3.3	20
27	Safety and Feasibility of MitraClip Implantation in Patients with Acute Mitral Regurgitation after Recent Myocardial Infarction and Severe Left Ventricle Dysfunction. <i>Journal of Clinical Medicine</i> , 2021, 10, 1819.	2.4	6
28	Effect of Clofazimine Concentration on QT Prolongation in Patients Treated for Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0268720.	3.2	16
29	Study protocol for a phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or without aspirin, for HIV-associated tuberculous meningitis [LASER-TBM]. <i>Wellcome Open Research</i> , 2021, 6, 136.	1.8	8
30	A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug-Drug Interactions With Antiretroviral and Antituberculosis Treatment. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1057-1065.	4.7	5
31	A Semimechanistic Model of the Bactericidal Activity of High-Dose Isoniazid against Multidrug-Resistant Tuberculosis: Results from a Randomized Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 1327-1335.	5.6	18
32	Relationship between Plasma and Intracellular Concentrations of Bedaquiline and Its M2 Metabolite in South African Patients with Rifampin-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0239920.	3.2	10
33	Pharmacokinetics and Target Attainment of SQ109 in Plasma and Human-Like Tuberculosis Lesions in Rabbits. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0002421.	3.2	12
34	Linezolid Population Pharmacokinetics in South African Adults with Drug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0138121.	3.2	9
35	Pharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 3237-3246.	3.0	26
36	Effect of Isoniazid Intake on Ethionamide Pharmacokinetics and Target Attainment in Multidrug-Resistant Tuberculosis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0027821.	3.2	4

#	ARTICLE	IF	CITATIONS
37	Pharmacokinetics and Drug-Drug Interactions of Abacavir and Lamuvudine Co-administered With Antituberculosis Drugs in HIV-Positive Children Treated for Multidrug-Resistant Tuberculosis. <i>Frontiers in Pharmacology</i> , 2021, 12, 722204.	3.5	3
38	Early antituberculosis drug exposure in hospitalized patients with human immunodeficiency virus-associated tuberculosis. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 966-978.	2.4	8
39	Real-World Safety and Efficacy of Transcatheter Mitral Valve Repair With MitraClip: Thirty-Day Results From the Italian Society of Interventional Cardiology (GISE) Registry Of Transcatheter Treatment of Mitral Valve Regurgitation (GIOTTO). <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 1057-1062.	0.8	23
40	Population Pharmacokinetics and Dosing of Ethionamide in Children with Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	7
41	Clofazimine pharmacokinetics in patients with TB: dosing implications. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3269-3277.	3.0	33
42	Effects of Pregnancy and Isoniazid Preventive Therapy on Mycobacterium tuberculosis Interferon Gamma Response Assays in Women With HIV. <i>Clinical Infectious Diseases</i> , 2020, 73, e3555-e3562.	5.8	9
43	Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3433-3457.	3.0	23
44	Population Pharmacokinetics of Cycloserine and Pharmacokinetic/Pharmacodynamic Target Attainment in Multidrug-Resistant Tuberculosis Patients Dosed with Terizidone. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	13
45	Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	5
46	Pharmacokinetics, Safety/tolerability, and Efficacy of high-dose Rifampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF). <i>Trials</i> , 2020, 21, 181.	1.6	14
47	Outcomes of TTVI in Patients With Pacemaker or Defibrillator Leads. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 554-564.	2.9	32
48	Combined Tricuspid and Mitral Versus Isolated Mitral Valve Repair for Severe Aortic Regurgitation and TR. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 543-550.	2.9	63
49	Population Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Pregnant South African Women with Tuberculosis and HIV. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	20
50	An Individual Participant Data Population Pharmacokinetic Meta-analysis of Drug-Drug Interactions between Lumefantrine and Commonly Used Antiretroviral Treatment. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	14
51	Commentary on: Transapical aortic perfusion using a deep hypothermic procedure during descending thoracic or thoracoabdominal aortic surgery. <i>Journal of Cardiovascular Surgery</i> , 2020, 61, 129-130.	0.6	0
52	MitraClip for radiotherapy-related mitral valve regurgitation. <i>Hellenic Journal of Cardiology</i> , 2019, 60, 232-238.	1.0	12
53	1-Year Outcomes After Edge-to-Edge Valve Repair for Symptomatic Tricuspid Regurgitation. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1451-1461.	2.9	160
54	A challenging mitral valve anatomy for percutaneous repair with MitraClip: cleft posterior leaflet. <i>European Heart Journal Cardiovascular Imaging</i> , 2019, 20, 1433-1434.	1.2	3

#	ARTICLE	IF	CITATIONS
55	Transcatheter edge-to-edge repair for reduction of tricuspid regurgitation: 6-month outcomes of the TRILUMINATE single-arm study. <i>Lancet, The</i> , 2019, 394, 2002-2011.	13.7	283
56	Transcatheter Versus Medical Treatment of Patients With Symptomatic Severe Tricuspid Regurgitation. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2998-3008.	2.8	302
57	A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	16
58	Pharmacokinetics, Safety, and Dosing of Novel Pediatric Levofloxacin Dispersible Tablets in Children with Multidrug-Resistant Tuberculosis Exposure. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	14
59	Mid-term outcomes (up to 5 years) of percutaneous edge-to-edge mitral repair in the real-world according to regurgitation mechanism: A single-center experience. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 427-435.	1.7	22
60	Anatomic Relationship of the Complex Tricuspid Valve, Right Ventricle, and Pulmonary Vasculature. <i>JAMA Cardiology</i> , 2019, 4, 478.	6.1	43
61	Initial Feasibility Study of a New Transcatheter Mitral Prosthesis. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1250-1260.	2.8	172
62	Low Antituberculosis Drug Concentrations in HIV-Tuberculosis-Coinfected Adults with Low Body Weight: Is It Time To Update Dosing Guidelines?. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	11
63	Transcatheter or surgical repair for degenerative mitral regurgitation in elderly patients: A propensity-weighted analysis. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2019, 158, 86-94.e1.	0.8	33
64	Effects of genetic variability on rifampicin and isoniazid pharmacokinetics in South African patients with recurrent tuberculosis. <i>Pharmacogenomics</i> , 2019, 20, 225-240.	1.3	32
65	Outcomes After Current Transcatheter Tricuspid Valve Intervention. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 155-165.	2.9	246
66	A Systematic Review on the Effect of HIV Infection on the Pharmacokinetics of First-Line Tuberculosis Drugs. <i>Clinical Pharmacokinetics</i> , 2019, 58, 747-766.	3.5	53
67	Transcatheter Repair of Severe Functional Tricuspid Insufficiency Using the Mitral Clip System. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 554-558.	5.3	6
68	Linezolid Pharmacokinetics in South African Patients with Drug-Resistant Tuberculosis and a High Prevalence of HIV Coinfection. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	19
69	The Tricuspid Valve Relationship With the Right Ventricle and Pulmonary Vasculature. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 564-565.	5.3	9
70	Anesthesiologic Management of Patients Undergoing Cardiac Transapical Procedures: Which Challenges in the Modern Era?. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2019, 33, 1883-1889.	1.3	1
71	Lopinavir-ritonavir super-boosting in young HIV-infected children on rifampicin-based tuberculosis therapy compared with lopinavir-ritonavir without rifampicin: a pharmacokinetic modelling and clinical study. <i>Lancet HIV</i> , the, 2019, 6, e32-e42.	4.7	19
72	Population Pharmacokinetic Properties of Sulfadoxine and Pyrimethamine: a Pooled Analysis To Inform Optimal Dosing in African Children with Uncomplicated Malaria. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	18

#	ARTICLE	IF	CITATIONS
73	Delayed Sputum Culture Conversion in Tuberculosisâ€‘Human Immunodeficiency Virusâ€‘Coinfected Patients With Low Isoniazid and Rifampicin Concentrations. <i>Clinical Infectious Diseases</i> , 2018, 67, 708-716.	5.8	34
74	Effect of genetic variation in <i>UGT1A</i> and <i>ABCB1</i> on moxifloxacin pharmacokinetics in South African patients with tuberculosis. <i>Pharmacogenomics</i> , 2018, 19, 17-29.	1.3	16
75	Beating-Heart Mitral Valve Repair Using a Novel ePTFE Cordal Implantation Device. <i>Journal of the American College of Cardiology</i> , 2018, 71, 25-36.	2.8	71
76	A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400 mg in Pregnant Women. <i>Clinical Pharmacokinetics</i> , 2018, 57, 1421-1433.	3.5	6
77	Levofloxacin Population Pharmacokinetics in South African Children Treated for Multidrug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	37
78	Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	16
79	Evidence-Based Design of Fixed-Dose Combinations: Principles and Application to Pediatric Anti-Tuberculosis Therapy. <i>Clinical Pharmacokinetics</i> , 2018, 57, 591-599.	3.5	26
80	Transcatheter Tricuspid Valve Repair With a Novel Cinching System. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, e199-e201.	2.9	14
81	Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 74, 139-148.	3.0	21
82	Transcatheter Mitral Valve Replacement in Patients With Previous Aortic Valve Replacement. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006412.	3.9	18
83	The Next Generation Scientist program: capacity-building for future scientific leaders in low- and middle-income countries. <i>BMC Medical Education</i> , 2018, 18, 233.	2.4	17
84	UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	40
85	Drug permeation and metabolism in <i>Mycobacterium tuberculosis</i> : Prioritising local exposure as essential criterion in new TB drug development. <i>IUBMB Life</i> , 2018, 70, 926-937.	3.4	27
86	Population Pharmacokinetics of the Antimalarial Amodiaquine: a Pooled Analysis To Optimize Dosing. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	21
87	Can We Improve Stavudine's Safety Profile in Children? Pharmacokinetics of Intracellular Stavudine Triphosphate with Reduced Dosing. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	3
88	Tricuspid valve imaging. <i>Minerva Cardioangiologica</i> , 2018, 66, 680-690.	1.2	4
89	Compare and contrast tricuspid and mitral valve anatomy: interventional perspectives for transcatheter tricuspid valve therapies. <i>EuroIntervention</i> , 2018, 13, 1889-1898.	3.2	30
90	POPULATION PHARMACOKINETICS OF GENTAMICIN IN PUPPIES DIAGNOSED WITH PARVOVIRUS ENTERITIS. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO2-13-1.	0.0	0

#	ARTICLE	IF	CITATIONS
91	Optimising mitral repair in functional regurgitation: transcatheter annuloplasty can counteract left ventricle-mitral ring mismatch. <i>EuroIntervention</i> , 2018, 14, 762-763.	3.2	0
92	Antimalarial Pyrido[1,2- <i>a</i>]benzimidazoles: Lead Optimization, Parasite Life Cycle Stage Profile, Mechanistic Evaluation, Killing Kinetics, and in Vivo Oral Efficacy in a Mouse Model. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 1432-1448.	6.4	36
93	Determinants of virological outcome and adverse events in African children treated with paediatric nevirapine fixed-dose-combination tablets. <i>Aids</i> , 2017, 31, 905-915.	2.2	7
94	Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1441-1449.	3.0	38
95	Multimodality imaging of the tricuspid valve with implication for percutaneous repair approaches. <i>Heart</i> , 2017, 103, 1073-1081.	2.9	52
96	Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	28
97	Pharmacokinetics of Sulfadoxine and Pyrimethamine for Intermittent Preventive Treatment of Malaria During Pregnancy and After Delivery. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 430-438.	2.5	23
98	Optimizing Research to Speed Up Availability of Pediatric Antiretroviral Drugs and Formulations. <i>Clinical Infectious Diseases</i> , 2017, 64, 1597-1603.	5.8	26
99	Percutaneous Tricuspid Valve Annuloplasty Under Conscious Sedation (With Only Fluoroscopic and) Tj ETQq1 1 0.784314 rgBT /Over	2.9	19
100	Transcatheter Treatment of Severe Tricuspid Regurgitation With the Edge-to-Edge MitraClip Technique. <i>Circulation</i> , 2017, 135, 1802-1814.	1.6	313
101	Use of Echocardiography for Guiding Percutaneous Tricuspid Valve Procedures. <i>JACC: Cardiovascular Imaging</i> , 2017, 10, 1194-1198.	5.3	15
102	Reverse Left Ventricular Remodeling Causing Severe Mitral Regurgitation After Bentall Procedure. <i>Annals of Thoracic Surgery</i> , 2017, 103, e85-e86.	1.3	0
103	Response to Lactation Status and Studies of Pyrimethamine Pharmacokinetics in Pregnancy. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 731-731.	2.5	3
104	The International Multicenter TriValve Registry. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1982-1990.	2.9	175
105	Mitral Valve-in-Ring Implantation With a Dedicated Transcatheter Mitral Valve Replacement System. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 2012-2014.	2.9	5
106	Systolic anterior motion after mitral valve repair: a predictive computational model. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2017, 25, 513-519.	1.1	7
107	Does implantation of a single clip provide reliable durability after transcatheter mitral repair? <i>European Journal of Cardio-thoracic Surgery</i> , 2017, 52, 137-142.	1.4	16
108	Prevention of TB using rifampicin plus isoniazid reduces nevirapine concentrations in HIV-exposed infants. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2028-2034.	3.0	9

#	ARTICLE	IF	CITATIONS
109	Optimization of the strength of the efavirenz/lamivudine/abacavir fixed-dose combination for paediatric patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 490-495.	3.0	4
110	Percutaneous bicuspidalization of the tricuspid valve using the MitraClip system. <i>International Journal of Cardiovascular Imaging</i> , 2017, 33, 227-228.	1.5	11
111	Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 190-199.	3.0	10
112	Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis. <i>Clinical Infectious Diseases</i> , 2017, 64, 1350-1359.	5.8	40
113	Mitral valve annuloplasty. , 2017, 2017, .		3
114	The big parade: emerging percutaneous mitral and tricuspid valve devices. <i>EuroIntervention</i> , 2017, 13, AA51-AA59.	3.2	13
115	Treatment Failure, Drug Resistance, and CD4 T-Cell Count Decline Among Postpartum Women on Antiretroviral Therapy in South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 31-37.	2.1	23
116	Plasma Efavirenz Exposure, Sex, and Age Predict Virological Response in HIV-Infected African Children. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 73, 161-168.	2.1	14
117	Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic Extraction. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 487-494.	3.2	61
118	Optimal results immediately after MitraClip therapy or surgical edge-to-edge repair for functional mitral regurgitation: are they really stable at 4 years?. <i>European Journal of Cardio-thoracic Surgery</i> , 2016, 50, 488-494.	1.4	31
119	Effect of mid-dose efavirenz concentrations and CYP2B6 genotype on viral suppression in patients on first-line antiretroviral therapy. <i>International Journal of Antimicrobial Agents</i> , 2016, 47, 466-472.	2.5	25
120	The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 185-198.	2.4	28
121	HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6050-6059.	3.2	25
122	MitraClip therapy and surgical edge-to-edge repair in patients with severe left ventricular dysfunction and secondary mitral regurgitation: mid-term results of a single-centre experience. <i>European Journal of Cardio-thoracic Surgery</i> , 2016, 49, 255-262.	1.4	39
123	Population Pharmacokinetics of Rifampin in Pregnant Women with Tuberculosis and HIV Coinfection in Soweto, South Africa. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1234-1241.	3.2	32
124	What is a "good" result after transcatheter mitral repair? Impact of 2+ residual mitral regurgitation. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2016, 151, 88-96.	0.8	89
125	Recent developments in percutaneous mitral valve treatment. <i>Expert Review of Cardiovascular Therapy</i> , 2016, 14, 217-228.	1.5	1
126	Percutaneous repair of the tricuspid valve using a novel cinching device: acute and chronic experience in a preclinical large animal model. <i>EuroIntervention</i> , 2016, 12, 918-925.	3.2	11

#	ARTICLE	IF	CITATIONS
127	Transcatheter direct mitral annuloplasty with Cardioband: feasibility and efficacy trial in an acute preclinical model. <i>EuroIntervention</i> , 2016, 12, e1428-e1434.	3.2	10
128	Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in Tanzania. <i>PLoS ONE</i> , 2015, 10, e0141002.	2.5	73
129	Comparison of Outcomes of Percutaneous MitraClip Versus Surgical Repair or Replacement for Degenerative Mitral Regurgitation in Octogenarians. <i>American Journal of Cardiology</i> , 2015, 115, 487-492.	1.6	29
130	Clinical and anatomical predictors of MitraClip therapy failure for functional mitral regurgitation: single central clip strategy in asymmetric tethering. <i>International Journal of Cardiology</i> , 2015, 186, 286-288.	1.7	31
131	Surgical treatment of paravalvular leak: Long-term results in a single-center experience (up to 14) Tj ETQq1 1 0.784314 rgBT /Overlock 0.8 88	0.8	88
132	Pharmacokinetics of Efavirenz and Treatment of HIV-1 Among Pregnant Women With and Without Tuberculosis Coinfection. <i>Journal of Infectious Diseases</i> , 2015, 211, 197-205.	4.0	69
133	In vivo efficacy and bioavailability of lumefantrine: Evaluating the application of Pheroid technology. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2015, 97, 68-77.	4.3	23
134	First-in-Man Implantation of a Tricuspid Annular Remodeling Device for Functional Tricuspid Regurgitation. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, e211-e214.	2.9	111
135	A translational "humanised" porcine model for transcatheter mitral valve interventions: the neo inferior vena cava approach. <i>EuroIntervention</i> , 2015, 11, 92-95.	3.2	9
136	Conventional surgery and transcatheter closure via surgical transapical approach for paravalvular leak repair in high-risk patients: results from a single-centre experience. <i>European Heart Journal Cardiovascular Imaging</i> , 2014, 15, 1161-1167.	1.2	62
137	Do Patients Undergoing MitraClip Implantation Require Routine ICU Admission?. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2014, 28, 1479-1483.	1.3	18
138	Transcatheter treatment of chronic mitral regurgitation with the MitraClip system. <i>Journal of Cardiovascular Medicine</i> , 2014, 15, 173-188.	1.5	9
139	Moxifloxacin Population Pharmacokinetics and Model-Based Comparison of Efficacy between Moxifloxacin and Ofloxacin in African Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 503-510.	3.2	38
140	Nutritional Supplementation Increases Rifampin Exposure among Tuberculosis Patients Coinfected with HIV. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3468-3474.	3.2	51
141	Percutaneous edge-to-edge repair in high-risk and elderly patients with degenerative mitral regurgitation: Midterm outcomes in a single-center experience. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2014, 148, 2743-2750.	0.8	25
142	Afterload Mismatch After MitraClip Insertion for Functional Mitral Regurgitation. <i>American Journal of Cardiology</i> , 2014, 113, 1844-1850.	1.6	48
143	Devices for Mitral Valve Repair. <i>Journal of Cardiovascular Translational Research</i> , 2014, 7, 266-281.	2.4	10
144	First-in-Man Transseptal Implantation of a "Surgical-Like" Mitral Valve Annuloplasty Device for Functional Mitral Regurgitation. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 1326-1328.	2.9	39

#	ARTICLE	IF	CITATIONS
145	Pharmacokinetic evaluation of lisinopril-tryptophan, a novel C-domain ACE inhibitor. <i>European Journal of Pharmaceutical Sciences</i> , 2014, 56, 113-119.	4.0	12
146	Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1339-1349.	3.0	53
147	Clinical outcomes of MitraClip for the treatment of functional mitral regurgitation. <i>EuroIntervention</i> , 2014, 10, 746-752.	3.2	97
148	Acute kidney injury following MitraClip implantation in high risk patients: Incidence, predictive factors and prognostic value. <i>International Journal of Cardiology</i> , 2013, 169, e24-e25.	1.7	20
149	TCT-700 Percutaneous Vs Surgical Repair For Degenerative Mitral Regurgitation In Octogenarians.. <i>Journal of the American College of Cardiology</i> , 2013, 62, B213-B214.	2.8	0
150	The pharmacokinetics of nevirapine when given with isoniazid in South African HIV-infected individuals [Short communication]. <i>International Journal of Tuberculosis and Lung Disease</i> , 2013, 17, 333-335.	1.2	13
151	A Time-to-Event Pharmacodynamic Model Describing Treatment Response in Patients with Pulmonary Tuberculosis Using Days to Positivity in Automated Liquid Mycobacterial Culture. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 789-795.	3.2	34
152	Model-based evaluation of the pharmacokinetic differences between adults and children for lopinavir and ritonavir in combination with rifampicin. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 741-751.	2.4	12
153	Pharmacometrics: Opportunity for Reducing Disease Burden in the Developing World: The Case of Africa. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2013, 2, 1-4.	2.5	19
154	Population Pharmacokinetics of Lopinavir and Ritonavir in Combination with Rifampicin-Based Antitubercular Treatment in HIV-Infected Children. <i>Antiviral Therapy</i> , 2012, 17, 25-33.	1.0	22
155	The disposition index: from individual to population approach. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2012, 303, E576-E586.	3.5	22
156	Population Pharmacokinetic Model for Adherence Evaluation Using Lamivudine Concentration Monitoring. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 481-484.	2.0	10
157	Reduced Antituberculosis Drug Concentrations in HIV-Infected Patients Who Are Men or Have Low Weight: Implications for International Dosing Guidelines. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 3232-3238.	3.2	91
158	Mitraclip therapy and surgical mitral repair in patients with moderate to severe left ventricular failure causing functional mitral regurgitation: a single-centre experience. <i>European Journal of Cardio-thoracic Surgery</i> , 2012, 42, 920-926.	1.4	85
159	Moxifloxacin Population Pharmacokinetics in Patients with Pulmonary Tuberculosis and the Effect of Intermittent High-Dose Rifapentine. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 4471-4473.	3.2	30
160	Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 465-476.	2.4	24
161	Direct access transcatheter mitral annuloplasty with a sutureless and adjustable device: preclinical experience. <i>European Journal of Cardio-thoracic Surgery</i> , 2012, 42, 524-529.	1.4	59
162	TCT-793 Effects of Preoperative Tricuspid Regurgitation on Mitral Regurgitation Treatment with the MitraClip Device in High-Risk Patients. <i>Journal of the American College of Cardiology</i> , 2012, 60, B231.	2.8	1

#	ARTICLE	IF	CITATIONS
163	Antimalarial and anticancer activities of artemisininâ€“quinoline hybrid-dimers and pharmacokinetic properties in mice. <i>European Journal of Pharmaceutical Sciences</i> , 2012, 47, 834-841.	4.0	35
164	Modelâ€“based approach to dose optimization of lopinavir/ritonavir when coâ€“administered with rifampicin. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 758-767.	2.4	20
165	Quality of life improvement is maintained up to two years after transcatheter aortic valve implantation in high-risk surgical candidates. <i>EuroIntervention</i> , 2012, 8, 429-436.	3.2	21
166	Transseptal access for MitraClipÂ® procedures using surgical diathermy under echocardiographic guidance. <i>EuroIntervention</i> , 2012, 8, 579-586.	3.2	19
167	Clinical trial experience with the MitraClip catheter based mitral valve repair system. <i>International Journal of Cardiovascular Imaging</i> , 2011, 27, 1155-1164.	1.5	12
168	Trans-apical and trans-axillary percutaneous aortic valve implantation as alternatives to the femoral route: short- and middle-term results. <i>European Journal of Cardio-thoracic Surgery</i> , 2011, 40, 49-55.	1.4	44
169	The <i>SLCO1B1</i> rs4149032 Polymorphism Is Highly Prevalent in South Africans and Is Associated with Reduced Rifampin Concentrations: Dosing Implications. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 4122-4127.	3.2	130
170	Alfieri stitch and its impact on mitral clip. <i>European Journal of Cardio-thoracic Surgery</i> , 2011, 39, 807-808.	1.4	23
171	Percutaneous mitral valve repair with the edge-to-edge technique. <i>Multimedia Manual of Cardiothoracic Surgery: MMCTS / European Association for Cardio-Thoracic Surgery</i> , 2010, 2010, mmcts.2009.004002.	0.1	0
172	Neochordae Implantation Made Easy with an Adjustable Device Early Report of Acute and Chronic Animal Experiments. <i>Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery</i> , 2010, 5, 287-290.	0.9	3
173	IVGTT glucose minimal model covariate selection by nonlinear mixed-effects approach. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2010, 298, E950-E960.	3.5	19
174	Concurrent prophylactic left atrial appendage exclusion: results from a randomized controlled trial pilot studyâ†. <i>European Journal of Cardio-thoracic Surgery</i> , 2009, 36, 553-557.	1.4	25
175	Quality of life of elderly patients following valve surgery for chronic organic mitral regurgitationâ†. <i>European Journal of Cardio-thoracic Surgery</i> , 2009, 36, 261-266.	1.4	28
176	Characterizing multisegment foot kinematics during gait in diabetic foot patients. <i>Journal of NeuroEngineering and Rehabilitation</i> , 2009, 6, 37.	4.6	57
177	Nonlinear Mixed Effects to Improve Glucose Minimal Model Parameter Estimation: A Simulation Study in Intensive and Sparse Sampling. <i>IEEE Transactions on Biomedical Engineering</i> , 2009, 56, 2156-2166.	4.2	14
178	Emergency transfemoral aortic valve-in-valve implantation with the balloon-expandable Edwardsâ€“Sapien valve. <i>Journal of Cardiovascular Medicine</i> , 2009, 10, 936-939.	1.5	7
179	Mitral annuloplasty. <i>Multimedia Manual of Cardiothoracic Surgery: MMCTS / European Association for Cardio-Thoracic Surgery</i> , 2009, 2009, mmcts.2008.003640.	0.1	9
180	Glucose Minimal Model population analysis: Likelihood function profiling via Monte Carlo sampling. , 2008, 2008, 4932-5.		3

#	ARTICLE	IF	CITATIONS
181	Transfemoral transcatheter aortic valve implantation using the balloon expandable SAPIEN transcatheter heart valve device. Multimedia Manual of Cardiothoracic Surgery: MMCTS / European Association for Cardio-Thoracic Surgery, 2008, 2008, mmcts.2007.003087.	0.1	4
182	Assessment of β -cell function in humans, simultaneously with insulin sensitivity and hepatic extraction, from intravenous and oral glucose tests. American Journal of Physiology - Endocrinology and Metabolism, 2007, 293, E1-E15.	3.5	276
183	Surgery of Left Ventricular Aneurysm: A Meta-Analysis of Early Outcomes Following Different Reconstruction Techniques. Annals of Thoracic Surgery, 2007, 83, 2009-2016.	1.3	27
184	Identification of IVGTT minimal glucose model by nonlinear mixed-effects approaches. , 2006, 2006, 5049-52.		4
185	Identification of IVGTT minimal glucose model by nonlinear mixed-effects approaches. Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 2006, , .	0.5	0
186	Surgical ablation of atrial fibrillation with a novel bipolar radiofrequency device. Journal of Thoracic and Cardiovascular Surgery, 2005, 130, 491-497.	0.8	45
187	A comparison of the population pharmacokinetics of rifampicin, isoniazid and pyrazinamide between hospitalized and non-hospitalized tuberculosis patients with or without HIV. Wellcome Open Research, 0, 7, 72.	1.8	0
188	Population pharmacokinetics of esomeprazole in patients with preterm preeclampsia. British Journal of Clinical Pharmacology, 0, , .	2.4	0
189	Pharmacokinetics of standard versus high-dose isoniazid for treatment of multidrug-resistant tuberculosis. Journal of Antimicrobial Chemotherapy, 0, , .	3.0	3